JUPITER is a large event-driven study with the newest statin and was stopped early because the lipid-lowering agent was shown to be more beneficial than placebo in reducing cardiovascular morbidity and mortality. Heartwire
Dr. Young educates the audience on analyses and interpretation of data from large complex studies, and explains bias, randomized controlled trials, observational studies, and confounders. Medscape Cardiology
According to an advisory statement on cardiopulmonary resuscitation from the American Heart Association, the public is now urged to start only chest compressions on any adult who collapses suddenly. Medscape Medical News
Results of a trial suggest that performing percutaneous coronary intervention in patients with myocardial infarction within 6 hours of receiving thrombolysis is superior to the wait-and-see strategy. Medscape Medical News
The single-tablet dual-mechanism therapy initiated in high-risk hypertensive patients significantly reduced the risk of morbidity and mortality by 20% compared with conventional therapy. Heartwire
The etiology of arrhythmogenic right ventricular dysplasia/cardiomyopathy involves environmental factors and genetic modifiers. Recent genetic advances, hypothetical disease mechanisms, and the role of clinical genetic testing in diagnosis and prognosis are reviewed. Nature Clinical Practice Cardiovascular Medicine
Patients in a randomized trial who have had a myocardial infarction kept an automated external defibrillator at home, but it did not seem to improve their chances of staying alive. Medscape Medical News
Results of a randomized trial show that antihypertensive treatment with a sustained-release formulation of a diuretic reduces fatal stroke, all-cause mortality, and heart failure in elderly patients. Medscape Medical News
The angiotensin receptor blocker was noninferior to the angiotensin-converting enzyme inhibitor, but the combination of the 2 drugs was linked with more adverse events without an increase in benefit. Medscape Medical News
Data from a trial on hypertension show that a single-tablet, dual-mechanism therapy initiated in high-risk patients with hypertension significantly reduces the risk for morbidity and mortality by 20%. Medscape Medical News
